💥 Your vote matters! ERA Full Active Members can vote for the ERA Ordinary Council member candidates until the start of the ERA Ordinary General Assembly (OGA), happening on:
📅 TOMORROW, 16:15 - 17:15 (BST)
Discover more 👉 https://t.co/w4uRJEqgLa
⏰ 2 DAYS TO #ERA26
💡 Where nephrology dares to think differently at the 63rd ERA Congress on June 3-6, 2026, both virtual and live in Glasgow.
🔎 Start now by checking out the Scientific Programme 👉 https://t.co/Iv7l81zrch
🆕 Join us for the 5th JSN and YNP (ERA) Joint Meeting!
📆 Friday, May 22, 2026, 12:00-1:15 PM (CEST) / 7 PM - 8:15 PM (JST)
📌 Topic: Differences in kidney dialysis / combined HD–PD - Perspectives from Japan and Europe
Register now 👉 https://t.co/mdefVzbSB0
📢 Don't forget to register for ERA Education - Kaunas 2026!
📆 Join us on September 24-25, 2026, in Kaunas, Lithuania, for the fourth ERA Education Meeting.
What you’ll get:
📚Educational sessions
🎓Certificate of attendance and EACCME®/UEMS credits
📍Registrations are reserved for ERA Members only.
Register now 👉 https://t.co/wIWcvSBJJo
📣 Save the date for the “Late Breaking Clinical Trials II” at #ERA26 on:
📅 June 5, 11:15–12:45 (BST)
Discover our Scientific Programme 👉 https://t.co/Iv7l81zrch
📢 Join us at the ERA e-seminar jointly organised with the @UEMSEurope Section of Nephrology: *ESENeph exam at European level*
📅 April 29, 2026 at 5:00 PM (CEST)
Register now 👉 https://t.co/kt1mK5MRKY
Recurrent IgAN after Transplantation
E-Seminar hosted by @ynptweets
Watch the full recording https://t.co/JaKkyTZBD5 (ERA members only)
Some highlights here
1st talk by Eleni Stamellou focused on pathophysiology, risk factors and prevention
recurrent IgA
🔵Common 5% at 5y, 10% at 10 y
🔵Higher with protocol biopsies-42% at 5y
🔵Early studies underestimated the impact on graft survival - more recent studies have HRs fo 2.04-3.44
Pathophysiology
🔵Mirrors native disease- galactose deficient IgA1 and 4 hit hypothesus
🔵Role of complement- C3 deposition almost universal, C4d is a strong predictor of graft loss
11/📩 Take-home message
👉🏻 Beyond renal and metabolic benefits, dapagliflozin shows a neutral effect on bone turnover and density over 12 months in non-diabetic CKD.
Read more about it in
📄 https://t.co/FXRcLnLX9U
#CKDMBD#SGLT2i
1/ 🤔 Do SGLT2i impact CKD-MBD?
👀 Check out this RCT that explores the effect of Dapagliflozin on CKD-MBD on non-diabetic patients.
Mohamed Elshayeb is the YNP author
Thread 🧵by @jt_nephrology@CKJsocial@ERAkidney
10/ 🚧 Limitations
•Small sample size and number of participants with eGFR < 30 ml/min/1.73m2
•Single-center, exploratory design
•Short follow-up for bone outcomes
•Limited evalutation microarchitectural skeletal effects